Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sparfloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | GSK3B | P49841 | 12/20 | 0.60 |
| ▸ | TOP2A | P11388 | 2/20 | 0.57 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sparfloxacin SCHEMBL29365159 | 1.00 | KCNH2 (1.00) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL1387460 | 1.00 | KCNH2 (1.00) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL2637186 | 1.00 | KCNH2 (1.00) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL28087316 | 0.99 | KCNH2 (0.98) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL9368141 | 0.99 | KCNH2 (0.98) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL9368128 | 0.99 | KCNH2 (0.98) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL28567061 | 0.99 | KCNH2 (0.98) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL28250745 | 0.98 | KCNH2 (0.96) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| Sparfloxacin SCHEMBL28471890 | 0.95 | KCNH2 (0.91) | KCNH2POLBCACNA1FMAPK1CACNA1D | |
| SCHEMBL13524323 | 0.93 | KCNH2 (0.87) | KCNH2POLBCACNA1FMAPK1CACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250388554-A1 | ANTIBACTERIAL COMPOUNDS, METHOD OF PRODUCTION AND USE THEREOF | NAT INSTITUE OF IMMUNOLOGY (IN) | 2025-12-25 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250367347-A1 | FIBRIN PATCH CONTAINING CORNEAL EPITHELIAL CELLS AND THE METHOD OF MANUFACTURING THEREOF | ACELLMED SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-12-04 | — | — | US | claimed |
| WO-1996036757-A2 | BARRIER WEBS | NEXTEC APPLICATIONS, INC. (US) | 1996-11-21 | — | — | WO | claimed |
| US-5532239-A | FOR THE TREATMENT OF NEPHROTIC SYNDROMES | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 1996-07-02 | — | — | US | claimed |
| WO-1996004924-A1 | IMPROVED ANTIINFECTIVE POLYOXYPROPYLENE/POLYOXYETHYLENE COPOLYMERS AND METHODS OF USE | CYTRX CORPORATION (US) | 1996-02-22 | — | — | WO | claimed |
| US-5478829-A | Solution of sparfloxacin, its preparation and salt of which it is composed | RHONE-DPC EUROPE (FR) | 1995-12-26 | — | — | US | claimed |
| WO-1995015182-A1 | ANTIINFECTIVE COMPOSITIONS AND METHODS OF USE | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| EP-0342649-B1 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER LAMBERT CO (US) | 1994-11-30 | — | — | EP | claimed |
| EP-0409254-B1 | RAPID-RELEASING ORAL PARTICLE PHARMACEUTICAL PREPARATION WITH UNPLEASANT TASTE MASKED | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| US-5179096-A | Treatment or pneumocystosis pneumonia | RHONE-POULENC SANTE (FR) | 1993-01-12 | — | — | US | claimed |
| WO-1992022819-A1 | DIAGNOSIS AND TREATMENT OF ARTERIAL CHLAMYDIAL GRANULOMA | BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON (US) | 1992-12-23 | — | — | WO | claimed |
| US-5082669-A | Ethyl cellulose plus cellulose ether or polyvinylpyrrolidone | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-01-21 | — | — | US | claimed |